Sicart Associates’s Nektar Therapeutics NKTR Stock Holding History

Sicart Associates’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-273	Closed	-$436K	–	91
2018 Q1	$436K	Hold	273	–	–	0.26%	68
2017 Q4	$245K	Buy	+273	New	+$161K	0.13%	95

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sicart Associates's NKTR Position: Q2 2018 in Review

Sicart Associates sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 273 shares — an estimated $436K sold.

Sicart Associates first reported a position in NKTR in Q4 2017 and held it in 2 quarters. The position peaked at $436K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

Sicart Associates reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
Sicart Associates sold 273 Nektar Therapeutics shares in Q2 2018, an estimated $436K.
Sicart Associates first reported a position in Nektar Therapeutics in Q4 2017 and held it in 2 quarters.
Sicart Associates's Nektar Therapeutics position peaked at $436K in Q1 2018.
379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Sicart Associates's 13F filing for Q2 2018, filed 19 Jul 2018.